Three emerging findings on the Mediterranean diet, the shingles vaccine and a new blood-thinning drug are reshaping how doctors think about stroke prevention.
Stroke is the fourth leading cause of death in the United States, and for most people, it arrives without warning. But a growing body of research suggests that the choices made years before a stroke occurs, what someone eats, which vaccines they receive and which medications they take, can meaningfully shift the odds.
Three recent studies are drawing particular attention from cardiologists and neurologists, each pointing to a different lever for reducing stroke risk. Taken together, they offer a more layered picture of prevention than the field has had before.
Mediterranean diet lowers stroke risk in women
A study published in Neurology Open Access followed more than 105,000 participants over time, tracking their eating habits and assigning each a score based on how closely they adhered to the Mediterranean diet. Among women, those who followed the dietary pattern most consistently showed a measurably lower risk of both ischemic stroke, caused by a blockage, and hemorrhagic stroke, caused by bleeding in the brain.
The Mediterranean diet centers on vegetables, fruits, whole grains, legumes, nuts and healthy fats, with olive oil as the primary fat source and limited red meat and processed foods. The cardiovascular benefits of this pattern are well documented. It tends to improve cholesterol levels, lower blood pressure and reduce chronic inflammation, all of which bear directly on stroke risk.
Registered dietitian Michelle Routhenstein has noted that the diet’s emphasis on nutrient-dense whole foods supports endothelial function, the health of the cells lining blood vessels, which plays a central role in preventing the arterial damage that contributes to stroke.
The shingles vaccine and its unexpected heart benefits
A separate study looked at whether the shingles vaccine offered any protection beyond its primary purpose of preventing the painful viral infection caused by the reactivation of the varicella-zoster virus. Researchers compared 275,304 vaccinated individuals against an equal number who had not received the shot and found that those who were vaccinated were less likely to experience major adverse cardiac events, including stroke.
The study was observational, meaning it identified a statistical association rather than proving a direct cause-and-effect relationship. That distinction matters in interpreting the findings. Still, the results add weight to existing public health guidance recommending that adults 50 and older receive the shingles vaccine, particularly those with underlying cardiovascular conditions.
Board-certified interventional cardiologist Dr. Cheng-Han Chen has pointed to this research as further support for vaccination in at-risk populations, even setting aside the direct benefits of shingles prevention.
Asundexian targets the cycle of recurring strokes
The third development addresses a different and particularly urgent problem. Roughly one in four strokes in the United States is a secondary stroke, meaning it occurs in someone who has already had one. Current standard care for secondary prevention has relied heavily on aspirin, a treatment with meaningful limitations.
Asundexian, an oral anticoagulant studied in research published in the New England Journal of Medicine, works through a different mechanism. It inhibits activated clotting factor XIa, a protein involved in the formation of the blood clots that cause most strokes. By targeting that specific step in the clotting process, the drug may reduce recurrence risk without some of the bleeding complications associated with older anticoagulants.
Dr. Ashkan Shoamanesh, a senior scientist at the Population Health Research Institute, described the findings as a meaningful step forward in secondary stroke prevention, an area where progress has been slower than many clinicians would like.
What the research adds up to
No single intervention eliminates stroke risk, and none of these three findings should be read as a replacement for comprehensive cardiovascular care. But the convergence of dietary, vaccine-based and pharmacological evidence gives both patients and physicians more to work with.
For someone managing elevated blood pressure or a history of cardiac events, the Mediterranean diet offers a low-risk, high-benefit starting point. For adults approaching or past 50, the shingles vaccine now carries a cardiovascular argument alongside its original purpose. And for stroke survivors navigating the risk of recurrence, asundexian represents a genuinely new option at a moment when the field has needed one.
The research is ongoing, and clinical guidance will continue to evolve. What these studies collectively suggest is that stroke prevention is no longer a single-track conversation.
